Gsa Capital Partners LLP Outlook Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$0.2 - $1.78 $51,878 - $461,721	259,394 New	259,394 $57,000
Q1 2023 May 12, 2023	SELL	$1.0 - $1.35 $179,946 - $242,927	-179,946 Reduced 64.78%	97,839 $106,000
Q4 2022 Feb 13, 2023	BUY	$0.87 - $1.33 $95,664 - $146,245	109,959 Added 65.52%	277,785 $300,000
Q3 2022 Nov 14, 2022	BUY	$1.02 - $1.26 $2,861 - $3,534	2,805 Added 1.7%	167,826 $205,000
Q2 2022 Aug 09, 2022	SELL	$0.91 - $2.01 $82,972 - $183,269	-91,179 Reduced 35.59%	165,021 $168,000
Q1 2022 May 11, 2022	BUY	$1.22 - $2.03 $56,312 - $93,700	46,158 Added 21.98%	256,200 $456,000
Q4 2021 Feb 14, 2022	BUY	$1.27 - $2.23 $266,753 - $468,393	210,042 New	210,042 $286,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.17B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.